Nano-X Imaging (NNOX) Company Report

Nano-X Imaging (NNOX) has initiated commercial deployment of its FDA and CE cleared Nano-X Arc and Arc-X digital multi-source 3D tomosynthesis imaging systems in the U.S. and EU markets.
The company offers a pay-per-use model where operators pay $30 per scan, with a reimbursable rate of $90-$110 per scan for the CPT code 76100. Mass production of the Arc-X is expected to accelerate in 2026.
For Q3 2025, Nano-X reported $3.5 million in revenue and held $55 million in cash and cash equivalents as of September 30, 2025, following a recent $50 million capital raise.
The company is transitioning its focus from R&D to commercialization of its products, aiming to achieve profitability and create shareholder value.

1 day ago

Transcript

Nano-X Imaging CFO Provides Business Update at Sidoti Conference

NNOX

Product Launch

New Projects/Investments

Revenue Acceleration/Inflection

Nano-X Imaging (NNOX) offers end-to-end diagnostic imaging solutions, including the FDA and CE-cleared Nano-X Arc and Arc-X digital multi-source 3D tomosynthesis imaging systems, AI solutions for chest, bone, and liver, teleradiology services, and an OEM business.
The company reported $3.5 million in revenue for the third quarter of 2025 and held $55 million in cash and cash equivalents as of September 30, 2025.
Nano-X is transitioning from an R&D company to a product company, with a primary focus on commercialization and achieving profitability.
Mass production of the Nanox.ARC-X is set to accelerate in 2026 in Thailand, following small-quantity production in Israel.

1 day ago

Transcript

Nano-X Imaging Ltd. Announces $15.0 Million Registered Direct Offering

NNOX

Nano-X Imaging Ltd. (NNOX) entered into a securities purchase agreement on November 23, 2025, with a single institutional investor for a registered direct offering.
The company sold 3,826,530 ordinary shares at a purchase price of $3.92 per share.
The offering closed on November 25, 2025, and is expected to generate approximately $15.0 million in gross proceeds.
The net proceeds from the offering are intended for working capital and general corporate purposes.
The company agreed to a 10-day non-issuance period for certain securities, and its officers and directors signed 30-day lock-up agreements.

Nov 25, 2025, 11:32 PM

6-K

Nano-X Reports Q3 2025 Results, Guides for 2026 Revenue, and Announces Acquisition

NNOX

Earnings

Guidance Update

M&A

Nano-X reported revenue of $3.4 million for Q3 2025, an increase from $3.0 million in Q3 2024. The GAAP net loss for Q3 2025 was $13.7 million, compared to a net loss of $13.6 million in Q3 2024.
The company provided 2026 revenue guidance of more than $35 million.
Nano-X announced the acquisition of VasoHealthcare IT (VHCIT) for a total consideration of up to $800,000, consisting of a $200,000 cash payment at closing and up to $600,000 in performance-based earnout payments. Vaso is expected to contribute approximately $4 million in revenues.
The AI business segment, with the addition of VasoHealthcare IT, is projected to achieve EBITDA break-even on a quarterly basis sometime in 2026, with Nano-X as a whole aiming to reach EBITDA break-even on a quarterly basis in 2027.
Nano-X is progressing toward deploying 100 systems worldwide by the end of 2025 and plans to unveil its next-generation platform, the Nano-X ARC X system, at the RSNA annual meeting.

Nov 20, 2025, 1:30 PM

Transcript

Nano-X Imaging Reports Q3 2025 Results and Provides 2026 Guidance

NNOX

Earnings

Guidance Update

M&A

Nano-X Imaging reported a GAAP net loss of $13.7 million and revenue of $3.4 million for the third quarter of 2025.
The company expects to generate a minimum of $35 million in revenue in 2026, with the recently acquired VasoHealthcare IT projected to contribute approximately $4 million.
Nano-X anticipates its AI business segment, including VasoHealthcare IT, to achieve quarterly EBITDA break-even in 2026, and the entire company to reach quarterly EBITDA break-even in 2027.
Key strategic developments include the acquisition of VasoHealthcare IT to bolster its AI business and customer operations, alongside new distribution agreements in the Czech Republic and France to strengthen its European market presence.

Nov 20, 2025, 1:30 PM

Transcript

Nanox Reports Q3 2025 Results, Provides 2026 Revenue Guidance, and Announces Acquisition

NNOX

Earnings

Guidance Update

M&A

For the third quarter of 2025, Nanox reported a GAAP net loss of $13.7 million and revenue of $3.4 million, with a non-GAAP net loss attributable to ordinary shares of $9.9 million. The company is guiding for more than $35 million in revenues for 2026.
Nanox announced an agreement to acquire VasoHealthcare IT (VHCIT) for a total consideration of up to $800,000, which includes a $200,000 cash payment at closing and up to $600,000 in performance-based earnout payments. This acquisition is expected to accelerate the deployment of Nanox.AI solutions.
The company projects its AI business segment, with the addition of VHCIT, will achieve EBITDA break-even on a quarterly basis in 2026, and Nanox as a whole is expected to reach EBITDA break-even on a quarterly basis in 2027.
Nanox is preparing to launch its next-generation platform, the Nanox.ARC X system, at the RSNA annual meeting and is progressing toward deploying 100 systems worldwide for clinical demo and commercial purposes by the end of 2025.

Nov 20, 2025, 1:30 PM

Transcript

Nano-X Imaging Ltd. Announces Q3 2025 Financial Results and 2026 Revenue Guidance

NNOX

Earnings

Guidance Update

M&A

Nano-X Imaging Ltd. reported revenue of $3.4 million for the third quarter of 2025, an increase from $3.0 million in the third quarter of 2024.
The company's net loss for the third quarter of 2025 was $13.7 million, a slight increase from $13.6 million in the comparable period of 2024.
A key business highlight for the quarter was the acquisition of Vaso Healthcare IT, aimed at expanding the company's AI solutions business.
For the full year 2026, Nano-X Imaging Ltd. expects revenues to reach $35 million.
As of September 30, 2025, the company held $55.5 million in total cash, cash equivalents, short-term and long-term deposits, and marketable securities.

Nov 20, 2025, 1:05 PM

6-K

Nanox Enters Distribution Agreement with EXRAY for Czech Market

NNOX

New Projects/Investments

Product Launch

NANO-X IMAGING LTD (Nanox) announced a distribution agreement with EXRAY s.r.o, a leading Czech medical imaging distributor.
Under the agreement, EXRAY will lead the market introduction, sales, and service of Nanox's advanced imaging solutions, specifically the Nanox.ARC, in the Czech Republic.
EXRAY is recognized as the number one supplier of digital radiography systems in the Czech Republic, with installations in over half of the country's 200 healthcare facilities.
This partnership represents a significant milestone in Nanox's European expansion, leveraging EXRAY's established market presence to expand access to high-quality, affordable imaging services.
The Nanox.ARC, a multi-source digital tomosynthesis system, is cleared for commercialization across the European Union following its CE Mark certification.